T A B L E O F C O N T E N T S

A B S T R A C T
Background
The measurement of severity and control of asthma in both children and adults can be based on subjective or objective measures. It has been advocated that fractional exhaled nitric oxide (FeNO) can be used to monitor airway inflammation as it correlates with some markers of asthma. Interventions for asthma therapies have been traditionally based on symptoms and/or spirometry.
Objectives
To evaluate the efficacy of tailoring asthma interventions based on exhaled nitric oxide in comparison to clinical symptoms (with or without spirometry/peak flow) for asthma related outcomes in children and adults.
Search methods
We searched the Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CEN-TRAL), MEDLINE, EMBASE and reference lists of articles. The last search was completed in February 2009.
Selection criteria
All randomised controlled comparisons of adjustment of asthma therapy based on exhaled nitric oxide compared to traditional methods (primarily clinical symptoms and spirometry/peak flow).
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. Relevant studies were independently selected in duplicate. Two authors independently assessed trial quality and extracted data. Authors were contacted for further information with response from one.
Main results
Two studies have been added for this update, which now includes six (2 adults and 4 children/adolescent) studies; these studies differed in a variety of ways including definition of asthma exacerbations, FeNO cut off levels, the way in which FeNO was used to adjust therapy and duration of study. Of 1053 participants randomised, 1010 completed the trials. In the meta-analysis, there was no significant difference between groups for the primary outcome of asthma exacerbations or for other outcomes (clinical symptoms, FeNO level and spirometry). In post-hoc analysis, a significant reduction in mean final daily dose inhaled corticosteroid per adult was found in the group where treatment was based on FeNO in comparison to clinical symptoms, (mean difference -450 mcg; 95% CI -677 to -223 mcg budesonide equivalent/day). However, the total amount of inhaled corticosteroid used in one of the adult studies was 11% greater in the FeNO arm. In contrast, in the paediatric studies, there was a significant increase in inhaled corticosteroid dose in the FeNO strategy arm (mean difference of 140 mcg; 95% CI 29 to 251, mcg budesonide equivalent/day).
Authors' conclusions
Tailoring the dose of inhaled corticosteroids based on exhaled nitric oxide in comparison to clinical symptoms was carried out in different ways in the six studies and found only modest benefit at best and potentially higher doses of inhaled corticosteroids in children. The role of utilising exhaled nitric oxide to tailor the dose of inhaled corticosteroids cannot be routinely recommended for clinical practice at this stage and remains uncertain.
P L A I N L A N G U A G E S U M M A R Y
Tailoring asthma interventions based on exhaled nitric oxide
In this review involving 1010 adults and children with asthma, we found that tailoring the dose of inhaled corticosteroids based on exhaled nitric oxide (compared to clinical symptoms with or without spirometry/peak flow) was beneficial in reducing the final (but not the overall) daily inhaled corticosteroid doses in adults. However in children inhaled corticosteroid dose was increased when exhaled nitric oxide guided strategy was used. There was no difference between groups in other asthma outcomes (exacerbations, spirometry, FeNO or symptom control). Thus tailoring the dose of inhaled corticosteroids based on exhaled nitric oxide cannot be routinely advocated.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults The mean ics dose at final visit in children and adolescents in the control groups was 804 mcg/day (budesonide equivalent)
The mean ICS dose at final visit in children and adolescents in the intervention groups was 140 higher (29 to 251 higher)
(3)
⊕⊕ low 3, 6, 7 *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidance High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
B A C K G R O U N D
The severity and control of asthma in both children and adults can be based on subjective or objective measures. A systematic review evaluating the efficacy of tailoring asthma interventions based on exhaled nitric oxide in comparison with the traditional reliance upon clinical symptoms of asthma (with or without spirometry/peak flow) will be useful to guide clinical practice.
O B J E C T I V E S
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing adjustment of asthma medications based on exhaled nitric oxide levels in comparison to clinical symptoms (with or without spirometry/peak flow).
Types of participants
Children and adults with 'classical asthma'. Exclusion criteria: eosinophilic bronchitis, asthma related to an underlying lung disease such as bronchiectasis and chronic obstructive airway disease, or diagnostic categories such as 'cough variant asthma' and 'wheezy bronchitis' where controversies exist.
Types of interventions
All randomised controlled comparisons of adjustment of asthma therapy based on exhaled nitric oxide compared to clinical symptoms (with or without spirometry/peak flow). Trials that included the use of other interventions were included if all participants had equal access to such interventions.
Types of outcome measures
Attempts were made to obtain data on at least one of the following outcome measures:
Primary outcomes
Asthma exacerbations during follow-up, or exacerbation rates.
Secondary outcomes
1. Objective data, 2. Symptom based data, 3. Medications. The proportions of participants and the mean clinical improvement were determined using the following hierarchy of assessment measures (i.e. where two or more assessment measures are reported in the same study, the outcome measure that is listed first in the hierarchy was used); i) Hospitalisation, acute presentations to an emergency facility for asthma; ii) Rescue courses of oral corticosteroids; iii) Symptomatic (Quality of life, Likert scale, asthma diary, visual analogue scale) -assessed by the patient (adult or child); iv) Symptomatic (Quality of life, Likert scale, asthma diary, visual analogue scale) -assessed by the parents/carers; v) Symptomatic (Likert scale, visual analogue scale) -assessed by clinicians; vi) Indices of spirometry, peak flow, airway hyperresponsiveness; and vii) Beta-agonist used. Dose of inhaled corticosteroid used was also described as a posthoc analysis
Search methods for identification of studies
Trials were identified from the following sources: 1. The Cochrane Airways Group Specialised Register of Trials 2. The Cochrane Central Register of Controlled Trials (CEN-TRAL) Issue 4, 2008 3. MEDLINE (1966 to February 2009 . Topic search strategy combined with the RCT search filter as outlined in the Airways Group module. 4. OLDMEDLINE (1950 to 65) . Topic search strategy combined with the RCT search filter as outlined in the Airways Group module. 5. EMBASE (1980 to February 2009 . Topic search strategy combined with the RCT search filter as outlined in the Airways Group module. 6. The list of references in relevant publications. 7. Written communication with the authors of trials included in the review. Searches for the electronic databases were based on the following terms: "asthma" AND ("exhaled nitric oxide" OR "FeNO" OR "FeNO" OR "airway inflammation") all as (textword) or (MeSH ) For the full search strategies see Appendix 1.
Data collection and analysis
Selection of studies
From the title, abstract, or descriptors, the literature search was reviewed independently in triplet (HP reviewed all and two sets of reviewers: AL; AK paired with CT) to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. From the full text using specific criteria, the same sets of reviewers independently selected trials for inclusion. There was no disagreement although it was planned that disagreement would have been resolved by third party adjudication.
Data extraction and management
Trials that satisfied the inclusion criteria were reviewed and the following information recorded: study setting, year of study, source of funding, patient recruitment details (including number of eligible subjects), inclusion and exclusion criteria, other symptoms, randomisation and allocation concealment method, numbers of participants randomised, blinding (masking) of participants, care providers and outcome assessors, dose and type of intervention, duration of therapy, co-interventions, numbers of patients not followed up, reasons for withdrawals from study protocol (clinical, side-effects, refusal and other), details on side-effects of therapy, and whether intention-to-treat analyses were possible. Data was extracted on the outcomes described previously and data from included studies was double entered into RevMan 5.0 for meta-analysis. Initial attempts to contact the corresponding authors were not successful, but further information was made available by one author from a new paper de Jongste 2009 for this update.
Assessment of risk of bias in included studies
Studies included in the review underwent quality assessment and entered into Risk of Bias 
Measures of treatment effect
For the dichotomous outcome variables of each individual study, relative and absolute risk reductions were calculated using a modified intention-to-treat analysis when the outcome event is a beneficial event. When the event is non-beneficial event (such as exacerbation), "treatment received" analysis was utilised. A modified intention-to-treat analysis assumes that participants not available for outcome assessment have not improved (and probably represents a conservative estimate of effect). An initial qualitative comparison of all the individually analysed studies examined whether pooling of results (meta-analysis) was reasonable. This took into account differences in study populations, inclusion/exclusion criteria, interventions, outcome assessment, and estimated effect size.
Data synthesis
The results from studies that met the inclusion criteria and reported any of the outcomes of interest were included in the subsequent meta-analyses. The summary weighted risk ratio and 95% confidence interval (fixed effects model) were calculated (Cochrane statistical package, RevMan 5.0). For Rate Ratios of common events whereby one subject may have more than one event, GIV was utilised. The Rate Ratios were taken from the published papers and the standard errors were calculated from confidence intervals or P values published in the papers. It was planned for cross-over studies, mean treatment differences would be calculated from raw data, extracted or imputed and entered as fixed effects generic inverse variance (GIV) outcome, to provide summary weighted differences and 95% confidence intervals. Numbers needed to treat (NNT) were calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (Cates 2003) . The outcome indices were assumed to be normally distributed continuous variables so the mean difference in outcomes could be estimated (weighted mean difference).
If studies reported outcomes using different measurement scales, the standardised mean difference was estimated. Any heterogeneity between the study results was described and tested to see if it reached statistical significance using a chi-squared test. The 95% confidence interval estimated using a random effects model was included whenever there are concerns about statistical heterogeneity. Heterogeneity is considered significant when the P value is <0.10 (Higgins 2005).
Subgroup analysis and investigation of heterogeneity
An a priori sub-group analysis was planned for a) adults vs children It was planned that sensitivity analyses be done to assess the impact of the potentially important factors on the overall outcomes: a) variation in the inclusion criteria; b) differences in the medications used in the intervention and comparison groups; c) analysis using random effects model; d) analysis by "strategy received"; e) analysis by "intention-to-treat".
R E S U L T S Description of studies
Results of the search
From the 2006 searches, the Airways Group specialised register/ search identified 1278 potentially relevant titles. After assessing the abstracts, 20 papers were obtained for consideration to be included into review, 4 papers were included. From 2009 searches, 52 additional abstracts were identified, 2 fulfilled the inclusion criteria..
Included studies
Six studies were included (see table "Characteristics of included studies"), four were uni-centre studies ( had a study duration of twelve months with participants being assessed 10 times;Smith 2005 had a study duration for a maximum of 2 years, with phase 1 running between 3 and 12 months and phase 2 having 6 visits in 12 months; and Szefler 2008 ran for 46 weeks with scheduled visits every 6 to 8 weeks Exacerbations were defined differently in each included study. An exacerbation was defined as: emergency visit, hospitalization or prednisolone course in de Jongste 2009. In Fritsch 2006 study asthma exacerbations were defined by 4 parameters: oral steroid courses, and/or off-scheduled visit because of asthma symptoms over the past 4 weeks, and/or increase of asthma symptoms from a symptom score 0 or 1 to a symptom score 2 and/or decline of FEV 1 (L) more than 10% compared to the previous visit. Pijnenburg 2005 defined an exacerbation as a deterioration in symptoms requiring oral prednisone course. Shaw 2007 also used a definition of an increase in symptoms requiring oral steroids or antibiotics. Smith 2005 defined exacerbations as minor or major; a minor exacerbation was defined as a daily asthma score of 2 or more on 2 or more consecutive days, whereas a major exacerbation was a daily asthma score of 3 or more on 2 or more consecutive days. Szefler 2008 combined admissions to hospital, unscheduled visits and oral prednisone use to define an exacerbation in their study. Two studies were in adults (Smith 2005 , Shaw 2007 ) and four children/adult studies (Fritsch 2006 , Pijnenburg 2005 , Szefler 2008 , de Jongste 2009 . We classified studies into children/adolescent studies based on the mean age reported as opposed to the entry criteria. Thus although Szefler 2008 study's entry criteria included young adults (up to 20 years), the mean age of the participants were 14·4 years (IQR 13-16) and hence included in the children/ adolescent analysis. 
Effects of interventions
ASTHMA EXACERBATIONS (Outcome 1)
Both adult papers (Shaw 2007; Smith 2005) used asthma exacerbations as the primary outcome and both described a reduction in various aspects of asthma exacerbations in the arm that utilised treatment based on exhaled nitric oxide (FeNO) when compared to the clinical symptom arm (control arm whereby treatment was based primarily on clinical symptoms). Both adult studies reported their FeNO group experienced fewer exacerbations than the clinical symptom group but the difference between groups was not significant. Outcomes are described below 1.1.1 Number of subjects who had one or more exacerbations (as defined by the author) over the study period Combined data from the two studies showed that the number of participants experiencing any exacerbations was not significantly different (P=0.76) between the FeNO group and clinical symptom group. Pooled OR estimate effect (random model) was 0.85 (95% CI 0.30 to 2.43). There was heterogeneity between the studies, I 2 = 63.9%. In the symptom control group 30 people out of 100 had one of more exacerbations over the study period over 52 weeks, compared to 27 (95% CI 12 to 51) out of 100 for the FeNO group, Figure 3 . There was also no significant difference between the groups for the outcome of occurrence of any exacerbation in adults (MD -0.14; 95% CI -0.41 to 0.12), and there was no significant heterogeneity between studies.
OBJECTIVE DATA (Outcome 2)
2.1.1 FEV 1 % predicted at final visit Data was only available from Smith et al which showed no significant difference between groups (MD 3.80 %Predicted; 95% CI -4.50 to 12.10). Shaw and colleagues reported that "there was no difference in FEV 1 between the groups over the duration of the study", but no details were provided. There was no significant difference between groups for symptom scores (SMD -0.14; 95% CI -0.42 to 0.14). At final visit there was a significant difference between the group's inhaled corticosteroid dose (budesonide equivalent in mcg/day) with lower doses in the group whose treatment was based on FeNO, ). However Shaw 2007 also reported an 11% increase in the total amount of inhaled corticosteroids used during the study (95% CI; -15% to 37%).
FeNO at final visit
MEDICATIONS (Outcome 4)
Inhaled corticosteroids dose at final visit
Children and Adolescents
Of the 838 children and adolescents recruited in these studies come, however they all used exacerbations as a secondary outcome. As described above the definition of exacerbations differed between the studies. Outcomes are described below.
1.1.2 Number of subjects who had one or more exacerbations (as defined by the author) over the study period Figure 2 Combination of data from the 4 studies found no significant difference between the groups (P=0.06), with 118 exacerbations in the FeNO group versus 140 in the control group, (OR 0.75; 95% CI 0.55 to 1.01). There was no significant heterogeneity between the studies. In the symptom control group 36 people out of 100 had one of more exacerbations over the study period (children) over 26-52 weeks, compared to 30 (95% CI 24 to 36) out of 100 for the FeNO treatment group, Figure 9 . Figure 4 For this outcome, data was only available from Szefler 2008 with no difference between the groups (MD -0.18; 95% CI -0.42 to 0.06).
Exacerbation rate
OBJECTIVE DATA (Outcome 2)
2.1.2 FEV 1 % predicted at final visit Figure 5 At final visit, there was no significant difference between the groups for FEV 1 % predicted (MD 1.81 %Predicted; 95% CI -0.64 to 4.25) in the meta-analysis of data from 3 studies, and there was no significant heterogeneity. In Fritsch 2006's study, FEV 1 was the primary outcome, but data could not be extracted. Howeverbut they reported no significant differences between the groups. 
FeNO at final visit
Symptom scores
Figure 7 Date combined from two studies (Pijnenburg 2005 , Szefler 2008 resulted in no significant difference between the groups for respiratory symptoms (SMD 0.04; 95% CI -0.11 to 0.20). Data from de Jongste 2009 study could not be added to the meta-analysis but they described no significant difference in percentage of symptom-free days during the whole study period between both groups. Likewise, Fritsch 2006 described no significant differences between the control and FeNO groups, and data could not be included in the meta-analysis.
Inhaled corticosteroids dose at final visit
Figure 8
Two studies (Fritsch 2006 , Pijnenburg 2005 reported the children in the control strategy as having lower mean daily dose of inhaled corticosteroids. Fritsch 2006 et al's data presented doses as medians (and IQR) and thus data was not combined. In Fritsch study, the daily ICS dose was 200 mcg higher in the FeNO group compared to the control group and authors reported that this difference was significant (P<0.01). The forest plot shows data from Pijnenburg's, Szefler's and deJongste's papers depicting a significant difference between the groups, with higher doses of inhaled corticosteroids in the FeNO group (MD 140.18; 95% CI 28.94 to 251.43 mcg/ day budesonide equivalent). There was, however heterogeneity in this outcome, Chi² = 3.46, df = 2 (P = 0.18); I² = 42%. A random effects model gave a wider confidence interval that included no difference between the groups (MD 121.89; 95% CI -32.24 to 276.03).
Sensitivity Analyses
Sensitivity analyses could not be performed for most specified criteria. Analysis using random effects is reported for individual outcomes above. Using intention to treat analysis did not alter direction or significance of events.
D I S C U S S I O N
This meta-analysis based on six studies in 1053 adults and children (with 1010 completed), has showed that tailoring the dose of inhaled corticosteroids based on exhaled nitric oxide (FeNO) in comparison with usual traditional methods (based primarily on clinical symptoms) did not significantly reduce exacerbations or improve FEV 1 or asthma symptoms. In children/adolescents there was a trend favouring the FeNO strategy in number of participants with one or more exacerbation, but this was at the expense of higher levels of inhaled corticosteroids. In adults, the FeNO based strategy enabled a reduction in the final (but not the overall) daily dose of inhaled corticosteroids .
Tailoring medications based on FeNO has been advocated in editorials (Szefler 2005) . This Cochrane review has shown that the benefits of utilising this strategy (as opposed to standard strategy based on clinical symptoms and simple tests like FEV 1 ) is at best modest and could potentially be harmful with increased ICS use in children. There was no significant difference between the two strategies in both adult and paediatric studies in the primary outcome of exacerbation, FEV 1 , FeNO levels or symptom control scores. The only significant beneficial difference found between groups was the final daily dose of ICS in adults. However this finding is limited as this was a post-hoc analysis. Even though the final ICS dose was lower at final visit, Shaw 2007 reported overall higher doses of ICS in the FeNO based strategy through the duration of study and was only lower on final visit. They related this to a proportion of patients who showed an elevated FeNO that was associated with a normal eosinophil count (identified by sputum eosinophil testing as a safety measure when the dose of ICS reached 2000 mcg/day). Furthermore in children where high ICS doses are of more concern due to potential adverse events, there was a significant increase in ICS dose in the FeNO strategy arm (mean difference of 140 ug (95% CI 29 to 251) of budesonide equivalent/day). In a previous systematic review we found that there was no significant difference in doses of ICS when asthma treatment was based on sputum eosinophils, as opposed to clinical symptoms (Petsky 2007). Although tests for FeNO are non-invasive and relatively easy to obtain measurements in children (when compared with obtaining and analysing sputum), it is not clear how to tailor the dose of inhaled corticosteroids based on exhaled nitric oxide in comparison to clinical symptoms. This is in contrast to tailoring asthma interventions based on sputum eosinophils where it is beneficial in reducing the frequency of asthma exacerbations in adults with asthma (Petsky 2007).
Limitations of review
This systematic review is limited to six studies with only 1010 subjects completing the trials. While the studies share some common issues, there are also significant differences, notably, the definition of asthma exacerbation, the cut off levels for FeNO were different, the control strategy and the steps for tailoring medications.
A U T H O R S ' C O N C L U S I O N S Implications for practice
The studies included in this review highlight the difficulties involved in tailoring the dose of inhaled corticosteroids based on exhaled nitric oxide, instead of primarily on clinical symptoms. At present this approach cannot be advocated as routine clinical practice.
Implications for research
Further RCT's in both adults and children with groups with other significant influences of FeNO taken into account (such as atopy) are required. A-priori pragmatic issues of clinical practice such as high vs low doses of ICS and to a lesser extent eosinophilic vs non-eosinophilic asthma should be considered with costs analysis for each sub-group. The design of future RCT's should preferably be parallel multi-centre studies and include outcomes of exacerbations, subjective measures (such as scores for asthma control and quality of life) as well as objective measures (FEV 1 etc). Analysis of costs and possible adverse events of inhaled and oral corticosteroids would also provide additional important information.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S
Pijnenburg 2005
Methods Randomised, double blind study evaluating whether titrating steroids on FeNO improved asthma management in children. Stratified by baseline FeNO (>30 or <30ppb) and dose of ICS (>400 or <400ug budesonide or equivalent daily dose) Neither subjects nor physicians were aware of which group they were randomised to There were 7 drop outs: 3 during run-in, 3 from FeNO group (1 admitted to ICU) and 1 from symptom group The study duration was 12 months, with 5 visits at 3 monthly intervals Participants 89 children randomised from 108 invited. FeNO group N= 39 : mean age 11.9 (SD 2. 9), 25 males, 14 females. Symptom group N= 46: mean age 12.6 (SD 2.8), 30 males, 16 females. Visiting outpatient clinic Inclusion: use of ICS at constant dose for at least 3 months preceding study, atopy defined as RAST class 2 or higher for at least 1 airborne allergan Interventions Children were run-in for 2 weeks, then 3 monthly visits. 
Shaw 2007
Methods Randomised, single blind controlled trial comparing exacerbation frequency and corticosteroid dosage in patients whose asthma management was based on measurements of FeNO to a control group where management was based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network treatment guidelines. Stratified by baseline sputum eosinophil count, baseline rescue steroid course in last year The subjects were blinded to which group they were randomised to, at completion the participants were asked to record which record they thought they had been assigned There were 15 drop outs, 6 in FeNO group and 9 in control group The study ran for 12 months and the subjects were assessed 10 times Participants 900 adults were contacted from general practice registers of which 118 were randomised. Low risk Single blind. Participants were assessed at completion of study regarding the group they thought they were assigned to, 49%
Shaw 2007 (Continued) were unsure of which group they were assigned, 33% correctly identified their group, and 18% incorrectly identified their group Incomplete outcome data addressed? All outcomes
Low risk
No missing outcome data.
Free of selective reporting? Unclear risk Insufficient information.
Free of other bias? Low risk Measurement of FeNO was successful on every occasion.
Smith 2005
Methods Randomised, placebo controlled, single blind study. It was a 2 phase study, with phase 1 varying in duration (3-12 months) where the dose of inhaled fluticasone was titrated down in a stepwise manner until the optimal dose was deemed to have been achieved. During phase 2 (12 months) optimal dose from phase 1 was continued and therapy was stepped up if asthma control was lost Subjects were blinded to which group they were assigned. In phase 1 there was 16 drop outs, 13 during run in and 3 during follow up. Phase 2 had 5 drop outs during the 12 months Participants 97 patients randomised from 110 patients recruited. 46 in FeNO group achieved optimal dose in phase 1 and 48 achieved optimal dose in control group Inclusion criteria: Inhaled corticosteroids for 6 months with no dose change in previous 6 weeks. Exclusion criteria: >4 courses of oral prednisolone in previous 12 months, admission to hospital in the last 6 months, any intensive care admissions, or cigarette smoking (current or past history of >10 pack-years)
Interventions Phase 1 Run-in period was for 6 weeks, after 2 weeks fluticasone 750ug/day was commenced. Visits were every 4 weeks until optimal dose was achieved. 
S O U R C E S O F S U P P O R T Internal sources
• Royal Children's Hospital Foundation, Brisbane, Australia.
External sources
• National Health and Medical Research Council, Australia.
• Queensland Smart State Clinical Fellowship, Australia. Support for AC
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
The outcome dose of inhaled corticosteroids was added post-hoc to the review. Risk of Bias tables have been added for the 2009 update. 
I N D E X T E R M S Medical Subject Headings (MeSH)
MeSH check words
Adult; Child; Humans
